Introduction
B-cell chronic lymphocytic leukemia (CLL) is considered a malignancy resulting from deregulated apoptosis. 1 Peripheral CLL cells are arrested in the G 0 /G 1 -phase of the cell cycle and do not display a high proliferative capacity. Two subgroups of patients can be identified based on mutations in the rearranged immunoglobulin heavy chain variable (IgV H ) genes. 2 Patients with leukemic cells bearing mutated IgV H genes have a significantly better overall survival rate than patients with unmutated IgV H genes. [3] [4] [5] DNA microarray analyses have revealed distinct gene expression profiles for the two CLL subgroups, but yielded no specific clues regarding the mechanisms underlying the prognostic differences or the deregulated apoptotic program. 5, 6 Various reports have addressed dysfunctional apoptosis in CLL, thereby mainly focusing on regulation and expression of antiapoptotic proteins. It is generally agreed that CLL cells contain high levels of Bcl-2, 7 which has been associated with aggressive disease and refractoriness to chemotherapy. 8, 9 In vitro incubation of leukemic cells with purine analogues or alkylating agents revealed alterations in expression levels of apoptosis regulators such as inversion of the Bcl-2:Bax ratio, 10 conformational changes of proapoptotic Bax and Bak, 11 and reduction of Mcl-1 and the inhibitor of apoptosis proteins (IAP) family member XIAP. 12, 13 The tumor suppressor gene p53 plays a central role in coupling of DNA damage or cellular stress to activation of apoptosis via the mitochondrial apoptosis pathway. Expression of several of the proapoptotic Bcl-2 family members such as Bax 14 and the BH3-only proteins Puma, [15] [16] [17] Noxa 18 and Bid 19 has been reported to be controlled by p53. Inactivation of p53 reportedly occurs in 15-25% of CLL patients which is caused either by p53 mutation 20 or by inactivation of the gene encoding ATM, 21 a kinase that regulates p53. In CLL, p53 dysfunction is associated with an adverse clinical outcome 22 and poor response to therapy. 20, 23 Earlier expression profiling studies on CLL cells with microarrays 5, 6, 24 did not involve responses of cells to stimuli or drugs. Later it was shown that Puma upregulation in response to radiation, an established inducer of p53, did not occur in CLL patients with mutations in either ATM or p53. 25 In contrast, the most recent array studies on in vitro DNA damage and in vivo fludarabine treatment indicated a p53-response, but did not address the contribution of Puma or other BH3-only members. 26, 27 Thus, to date the knowledge on various proapoptotic BH3-only members in response to clinically relevant stimuli in CLL is incomplete. Yet, it is plausible that the balance between these and other pro-and antiapoptotic regulators determines the fate of a cell. We therefore aimed to quantify expression of all known direct regulators of apoptosis, using a reverse transcriptase-multiplex ligation-dependent probe amplification assay (RT-MLPA). 28, 29 This procedure targets 34 apoptosis-related genes, including the complete Bcl-2 and IAP family and miscellaneous proteins such as Flip, PI-9, AIF and Apaf. With this technique the apoptosis gene expression profile of CLL cells with either intact or dyfunctional p53 function was investigated in relation to (1) normal tonsillar B cells, (2) IgV H mutation status and (3) incubation with therapeutic drugs. We show that CLL cells display major aberrations not only in antiapoptotic but also in proapoptotic genes involved in both the death receptormediated and mitochondrial apoptosis pathways. Moreover, upon cytotoxic drug administration and apoptosis induction, only Puma expression was strongly augmented in a p53-dependent manner, and this was more prominent in cells expressing mutated IgV H genes.
Patients, materials and methods

CLL patients and isolation of leukemic and normal B cells
Peripheral blood was drawn from CLL patients at the Academic Medical Center, Amsterdam, The Netherlands, and at the UCSD CLL cells and normal B cells were enriched to 495% purity from PBMCs via negative depletion as described previously. 30 In brief, T cells, monocytes and granulocytes were depleted using a-CD3, a-CD14 and a-CD16 immunomagnetic beads and a magnetic particle concentrator (both Dynal A.S., Oslo, Norway). Purified leukemic cells contained 497% of CD5 þ CD19 þ B cells. Tonsillar B cells were separated into the following B cell subsets:
Fractions of 495% purity were obtained after staining with saturating amounts of CD19-PerCPCy5, CD38-PE (both Becton Dickinson, San Jose, CA) and a-IgD-FITC mAbs (Dako A/S, Glostrup, Denmark) and sorting on a MoFlow (Dako Cytomation, Ford Collins, CO, USA). Peripheral B cells were obtained via CD19 þ staining and sorting to 495% purity.
V H gene analysis
Of each patient the V H gene mutation status was determined by PCR-and sequence-analysis as described previously. 31 The sequences were compared with published germline sequences, using the Vbase database and DNAplot on the Internet (http:// www.mrc-cpe.cam.ac.uk/DNAplot) to identify mutations. Patients were considered to express unmutated IgV H genes when o2% of the V H family sequence was mutated when compared to the most homologous germline sequence.
Determination of p53 status
FISH analysis was performed and p53 status was functionally tested. CLL cells were irradiated (5 Gy), and analyzed 24 h later for upregulation of CD95 by FACS, and upreglation of p21 and p53 by Western blotting using standard procedures. 21 A sample was considered dysfunctional for p53 when upregulation of p21 and CD95 was absent. Samples displaying heterogenous responses were excluded from analysis.
Analysis of apoptosis
Cell viability was analyzed in duplicate samples as described, 32 using Annexin-V-FITC (APOPTEST-FITC, ImmunoQuality Products, Groningen, The Netherlands) and propidium iodide (PI) (Sigma, St Louis, MO, USA). Alternatively, apoptosis was determined by a combined measure of decreased mitochondrial membrane potential by DiOC 6 (Molecular Probes, Eugene, OR, USA) and PI exclusion. No differences among patient samples were noted using these different methods of apoptosis read out.
In cell stimulation experiments freshly isolated, or thawed cells in case of the p53-deficient samples, purified CLL cells were used at a concentration of 1.0 Â 10 6 cells/ml in 25-cm 
MLPA probes and reaction
MLPA probes consist of two oligonucleotides that anneal to adjacent sites on a target sequence and are then ligated by a heat stable ligase. Each ligated probe gives rise to an amplification product of unique length, and the resulting DNA mixture is analyzed by capillary sequencer and standard software for identification and relative quantification of the amplicons. 28 Each MLPA probe consists of one short synthetic oligonucleotide (Biolegio, Malden, The Netherlands) and one phage M13 derived long probe oligonucleotide. Preparation of the M13-derived MLPA probe oligonucleotides and all probes used in the apoptosis gene probe set, and detailed reaction conditions have been described elsewhere; see also Supplementary Table 2 . 28, 29 In brief, RNA samples (40-60 ng of total RNA) were first reverse transcribed using a gene-specific probe mix. The resulting cDNA was annealed overnight at 601C to the MLPA probe mix (1-4 fmol of each synthetic oligonucleotide and M13-derived oligonucleotide in TE). Annealed oligonucleotides were ligated by adding Ligase-65 (MRC-Holland, Amsterdam), and incubation at 541C for 15 min. Ligation products were amplified by PCR (33 cycles, 30 s at 951C; 30 s at 601C and 1 min at 721C) with one unlabeled and one FAM labeled primer (10 pMol).
Analysis of MLPA data
After the PCR stage, aliquots of samples were mixed with Genescan-500 ROX size standards and analyzed on a Applied Biosystems 3100 capillary sequencer (Applied Biosystems, Warrington, UK) in Genescan mode. Data were analyzed with Genescan and Genotyper software packages (Applied Biosystems), successively, and exported for further analysis with Microsoft Excel Spreadsheet software. Normalization to correct for fluctuations in total signal between samples was performed by setting the sum of all data per sample at 100%, and individual peaks were calculated relative to the 100% value. When required, signals below the detection limit obtained for samples cultured in medium were assigned a value corresponding to the threshold value for noise cutoff in Genescan. Previous analyses have shown that the signal ratios for the genes analyzed are independent of the number of PCR cycles (range [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , and that fluctuations in signal for one gene (range 0-12%) do not influence the other signals. 29 Thus, at least within these limits efficiency of PCR-amplification is equal for all ligation products, and the calculated peak areas correspond to a high degree with the amount of mRNA originally present in the sample. For data presentation, gene expression levels were calculated relative to levels of peripheral B cells (PBB) by subtracting the average of 5 PBB samples for each gene. The resulting data were imported in the TIGR Multiexperiment viewer version 2.2 (www.tigr.org/ software/tm4).
Validation of RT-MLPA procedure to study gene induction
To explicitly validate the RT-MLPA procedure with respect to gene expression and induction patterns, a spiking experiment was performed. Bid cDNA obtained by PCR (forward primer AGGCCATGGACTGTGAGG, reverse TCAGTCCATCCCATTT CTGG) was cloned in pGEM-T vector (Promega, Leiden, The Netherlands), and in vitro transcribed with a T7 Megascript kit (Ambion, Austin, TX, USA). RNA concentration was spectroscopically determined. Appropriate dilutions (range 0.8-500 fg RNA) were added to RNA from a CLL patient obtained at t ¼ 0 and after 24 h culture of cells in the presence of fludarabine. Analysis of these samples showed that a single signal could be artificially increased up to levels exceeding 50% of total without grossly disturbing the outcome (see legend to Supplementary Figure 1) . Moreover, over the range of added RNA, the ratios of gene induction observed in the presence of fludarabine were maintained (Supplementary Figure 1 , for details on induction of Bax and Puma, see Results section). These data corroborated that irrespective of fluctuations in one gene, expression and induction responses of other target genes in the RT-MLPA probemix can reliably be quantified.
Western blotting
Western blotting was performed as described previously, 33 after separation of protein samples on 13% SDS-PAGE gels. Mabs against Noxa were purchased from Biocarta (Carlsbad, CA, USA), against Bmf from Alexis (Leiden, The Netherlands) and against Tubulin from Sigma.
Generation of Puma antiserum
Puma-b was cloned via RT-PCR from U2OS cells with primers CCATGGCCAAATTTGGCATGGGGTCTG and GAATTCCT AATTGGGCTCCATCTCG and inserted via NcoI and EcoRI digestion into the pET30 bacterial expression vector (Novagen, Darmstadt, Germany), using standard procedures. Puma-b protein was purified via Ni 2 þ -Sepharose affinity chromatography according to the manufacturers instructions (Qiagen). Rabbits were immunized with 100 mg Puma protein in 1 ml PBS and 1 ml montanide (Seppic, Paris, France) as adjuvans. After 3 monthly boosts, their sera showed prominent reaction on Western blot against both the bacterial immunogen as well as against overexpressed Puma protein in U2OS cells. The most sensitive serum was used at 1:500 dilution to detect Puma in lysates of CLL patients.
Statistical analyses
Kruskal-Wallis test was used for analysis of differences between 42 groups after which two-sided Mann-Whitney U test was used to further identify differences between two groups. The Wilcoxon signed-rank test was used to compare the differences between paired samples. P-values o0.05 were considered statistically significant.
Results
Profiling of apoptosis genes in CLL and normal B cell subsets
Expression profiling of purified B cells from 19 CLL patients with intact p53 and six patients with dysfunctional p53 response was performed on fresh samples, after 24 h of culture in medium, and after 24 h in the presence of the drug fludarabine. Results were compared with normal tonsillar B cell subsets and peripheral B cells. Normalized levels for each gene were assigned a positive or negative value by subtracting averaged values obtained in normal peripheral B cells, and the calculated results for all samples are visualized in Figure 1 . Additional information on averaged relative expression values in all samples is given in Supplementary Figures 2-4 . A subset of genes displayed altered expression profiles among the tonsil subsets and the CLL cells. To illustrate that the MLPA procedure can be used to compare different cell populations, we focus in a Supplementary section on this subset of genes involved in the death receptor pathway and the mitochondrial pathway of apoptosis (Flip, Bid, Bcl-2, Bfl-1, Bik, Mcl-1), as well as Survivin. This also allows interpretation of the MLPA data in the context of prior studies. Taken together, the data indicate that both proand antiapoptosis genes are modulated during germinal center maturation, 34 and expression of some of these is altered in CLL cells in a way that suggests increased protection from mitochondrial cytochrome c release.
Overexpression of proapoptotic BH3-only genes Bmf and Noxa
In strong contrast to the antiapoptotic profile mentioned above, significant overexpression was observed in CLL cells of two BH3-only apoptogenic genes, Bmf and Noxa. While Bmf expression was low in normal B-cell subsets, in CLL cells Bmf was abundantly expressed with levels ranging from 1.5 to 7.8% of total signal (Figure 1 and Supplementary Table 3 ). This represents an averaged increase of 4.2-fold. The second BH3-only gene overexpressed in CLL cells was the putative p53-inducible gene Noxa. In normal B cell subsets, Noxa gene expression levels already ranged from 2.3 to 9.5%, but in CLL cells this was even further enhanced (range 1.2-28.3%, averaged 2.6-fold increase). The increase in Bmf and Noxa transcripts was validated at the protein level. In Figure 2 (top panel) a Bmf doublet at 20-25 kD was observed in five CLL samples, which was absent in the tonsil sample. The double bands most probably represent splice variants of Bmf as reported recently. 35 The blot was reprobed for presence of Noxa (Figure 2  middle panel) , which was also increased in patients relative to the tonsil sample.
Statistical analysis of leukemic samples did not point to a correlation between the expression levels of Bmf, Noxa or any antiapoptotic Bcl-2 family member (data not shown). When averaged, CLL samples displayed strongly increased Bmf or Noxa transcripts, but some individual patients had levels within the range of normal tonsil B cells. In addition, the aberrantly expressed apoptosis genes described here did not correlate with RAI stage, Zap70 and CD38 expression or IgV H mutation status.
Cytotoxic drug-induced upregulation of Puma
To identify changes in expression profile related to induction of apoptosis, CLL cells were cultured in vitro for 24 h either in the absence or presence of the purine analogue fludarabine monophosphate. This drug is currently applied in CLL and induces DNA damage resulting in apoptosis via inhibition of DNA synthesis. Consistent with previous reports, 11, 36 in vitro culture of CLL cells caused spontaneous apoptosis. Incubation of cells with fludarabine considerably enhanced programmed cell death ( Figure 3a) . As a control, the general caspase inhibitor z-VAD was added to cultured cells of two patients, which as expected blocked apoptosis execution (not shown). No significant difference in percentage of apoptotic cells was observed between IgV H unmutated (n ¼ 9) and mutated (n ¼ 10) CLL groups (not shown).
The overall apoptosis gene expression profile of CLL cells after in vitro culture in the absence or presence of fludarabine was quite similar to that observed immediately after isolation. Drug treatment resulted in significant upregulation of only two apoptogenic genes: Bax and Puma (Figure 1 and Supplementary  Figure 3) . While Bax showed a B2-fold induction in expression (Po0.0005), a drastic induction of the p53-responsive BH3-only gene Puma was observed (Figure 3b ). Already after culture in medium for 24 h, expression of this apoptogenic gene was induced on average four-fold (Po0.001). Treatment of cells with fludarabine further enhanced Puma expression in all samples compared to cells in medium only (averaged 19-fold induction; Po0.01), in association with apoptosis induction. Importantly, during in vitro culture of cells in the presence of z-VAD, Puma upregulation in both spontaneous and drug-induced apoptosis was maintained, demonstrating that it occurred independently of caspase activation.
The induction of Puma protein is demonstrated in Figure 3c in samples from two patients. Compared to very low or undetectable levels directly after isolation of CLL cells, Puma protein increased after 4-8 h of treatment with fludarabine. In CLL cells, predominantly the 20 kD Puma-a isoform was observed. 15 Previously, it was shown that Puma has a short half-life 16 and in agreement with this, addition of the protease inhibitor TPCK to limit proteasome activity increased Puma protein levels. 
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Puma and apoptosis induction by cytotoxic drugs is p53 dependent, and varies according to IgV H -status Puma was originally described as an early p53-responsive gene, 15, 16 but subsequently other stimuli such as serum or cytokine deprivation and glucocortoids were also reported to influence Puma expression. 17, 37, 38 Therefore, we monitored Puma induction in CLL cells with dysfunctional p53. It appeared that the low-level Puma induction after culture in medium only was independent of the p53 status, but that further upregulation by the cytotoxic drug fludarabine required functional p53 ( Figure 4) . In correlation, Bax induction by fludarabine treatment was also absent in p53-deficient cells (see Supplementary Figure  4) . At the functional level it was shown that the percentage of spontaneous apoptosis in p53 dysfunctional samples was in the same range as in p53 wild-type samples. However, no significant further increase in apoptosis was observed after treatment with fludarabine, consistent with previous reports. 21, 39 The percentage of apoptic cells in p53-deficient samples was 24713%, at t ¼ 24 h 55714%, and in the presence of fludarabine 57711%. Degree of drug-induced Puma upregulation correlates with IgV H mutation status, and is absent in p53-deficient CLL. Data concerning Puma induction were separated according to IgV H unmutated (white bars, n ¼ 9) and mutated (black bars, n ¼ 10) CLL patients, and compared with CLL samples with known p53 dysfunction (hatched bars, n ¼ 6). Data represent fold Puma induction7s.d. in relation to the level in fresh samples, which was set at 1 for each sample. At t ¼ 0 and after 24 h in medium induction of Puma was similar in the three groups. In presence of fludarabine Puma expression was further enhanced, except in p53-deficient samples. Average druginduced Puma induction differed between CLL patient groups (Po0.01 as indicated with an asterisk, n).
Interestingly, we noticed a clear distinction in magnitude of Puma upregulation according to IgV H mutation status. Compared to the t ¼ 0 sample, Puma induction was 1578-fold in unmutated IgV H samples (n ¼ 9) and 41724-fold in mutated samples (n ¼ 10, Po0.01). In the p53-deficient samples, druginduced Puma upregulation was virtually absent (3.872.5 compared to 2.371.8 for medium only), regardless of IgV H status (see Figure 4) . Thus, the distinct Puma upregulation in mutated vs unmutated CLL samples cannot be explained simply by potential differences in p53-status among the two patient groups.
Discussion
In the present study, we used a recently described multiplex technique 29 to quantify and compare an overall apoptosis gene expression profile of normal tonsillar B cells and CLL cells. The quantitative capacity of the RT-MLPA assay was further validated here by spiking CLL RNA samples with a single exogenous RNA, showing that even when one signal is dominant, other gene expression and induction patterns are maintained to a high degree. The RT-MLPA procedure targets almost the entire Bcl-2 and IAP families and we observed several novel differences between CLL and subsets of normal tonsillar B cells. The absence of Bik in CLL was also reported in a recent study of a number of Bcl-2 family genes in CLL. 40 Lack of Bid and Bik, together with high constitutive expression of Bcl-2 and Flip, may well contribute to the nonresponsiveness of death-receptor and BCR-mediated apoptosis pathways in CLL cells. A novel finding was that next to these protective changes the majority of CLL cases showed increased expression of proapoptotic BH3-only members Bmf and Noxa, which was confirmed at the protein level. Finally, we report for the first time a strong p53-dependent Puma induction upon treatment with a clinically relevant drug, and that the degree of Puma upregulation correlated with IgV H mutation status.
Based on apoptosis regulatory genes alone, germinal center B cells could be distinguished from both naïve and memory B cells by the absence of Bcl-2 and the augmented expression of Bik and Survivin (Figure 1 and Supplementary Table 3) , fully consistent with events during the germinal center reaction. 34, 41 Crosslinking of CD40 on B cells normally induces expression of antiapoptotic Bfl-1, and protects from BCR-mediated apoptosis. 42, 43 In comparison to tonsillar and peripheral B-cell subsets, Bfl-1 was minimally expressed, implying that the bulk of circulating CLL cells had not been in recent contact with CD40L. Yet, in vitro CD40 crosslinking of leukemic cells leads to upregulation of Bfl-1, 44 which shows that this pathway is intact. These observations suggest that continuous contact with CD40L is not a dominant factor in in vivo survival of circulating CLL cells. Sanz et al 45 found decreased levels of Bcl-2, Bfl-1 and Mcl-1 in CLL cells undergoing spontaneous apoptosis, which was not observed by us using a 4two-fold change in signal level as criterium for significance (see Figure 1 and Supplementary data). Possibly, results of the semiquantitative RNAse-protection approach can differ from the MLPA procedure when using RNA from apoptotic cells. In normal peripheral B cells, the expression of Bcl-2, Bfl-1, Noxa and Bmf was quite similar to the tonsil subsets while levels of Flip, Bik and Survivin resembled the CLL cells (see Supplementary Table 3 ), which may suggest that the first group is indeed aberrantly regulated in the malignant cells.
We found strongly augmented expression in CLL of the two BH3-only members Bmf and Noxa, which by itself appeared insufficient for apoptosis induction as cell viability measured immediately after isolation was generally 490%. However, during in vitro culture CLL cells quickly underwent spontaneous and drug-induced apoptosis, in association with upregulation of Puma. Therefore, we propose that in CLL (1) imminent apoptosis is constantly blocked by protective regulators and (2) additional proapoptosis regulator(s) are required to tip the balance. The first point is supported by high levels of Bcl-2 and Mcl-1, which can sequester Bmf and Noxa and thus prevent mitochondrial apoptosis. 18, 46 Overexpression of Bcl-2 is a known feature in CLL, 7 and was confirmed by RT-MLPA analysis. High Mcl-1 protein expression in CLL has been correlated with failure to achieve complete remission after single-agent therapy. 9 Although high Mcl-1 mRNA levels were detected in CLL samples in our study, they did not significantly differ from tonsil B-cell subsets (Figure 1 and Supplementary Figures 2-4) , indicating that Mcl-1 is not specifically deregulated in CLL.
The second point is illustrated by the upregulation of Puma that accompanies apoptosis of CLL cells. In addition to its reported p53-responsiveness, 15, 16 Puma can be induced upon serum deprivation. 17 In studies with knockout mice, 37, 38 involvement of Puma in apoptosis caused by glucocorticoids, PMA and cytokine deprivation was reported. We observed Puma upregulation during spontaneous apoptosis in vitro, and this was maintained in CLL cells with a defective p53-response (Figure 4 ), arguing that indeed another signaling pathway is responsible. Addition of cytotoxic drugs known to activate p53 strongly enhanced Puma expression, in a caspase-independent manner, and further augmented apoptosis. Together, these results show for the first time in a primary malignancy the association between drug-induced, p53-dependent upregulation of Puma and execution of apoptosis. BH3-only proteins are essential for the induction of apoptosis but their exact mechanism of action is not known. Bmf, Noxa and Puma have all three been reported to interact with antiapoptotic but not with proapoptotic Bcl-2-family members. 15, 16, 18, 46 By sequestering protective Bcl-2 members, a shift of equilibrium towards apoptosis may occur. In adherent cells that undergo apoptosis after detachment, Bmf is released from the cytoskeletal components whereupon it associates with Bcl-2. 46 Interestingly, CLL is characterized by modifications in the cytoskeleton organization such as the formation of F-actincontaining podosomes and a substantial lack of microfilaments which have been related to the malignant transformation of CLL cells. 47 Future studies will determine if in CLL cells dysregulation of Bmf plays a role in blocking or predisposing to apoptosis. We did not observe Bmf protein in freshly isolated tonsil B cells, but transcriptional upregulation of Bmf in B cells and CLL cells by serum deprivation was reported recently. 35 In agreement with our studies two protein variants were described, although under our experimental conditions no change in Bmf expression was found. It should be noted that the probes used in the MLPA procedure do not discriminiate between Bmf splice variants. In our studies, no significant drug-mediated induction of either Noxa or Bid was observed, so at least in CLL cells these genes appear not to be direct targets of p53. 18, 19 Also in primary human T-lymphocytes we have not observed significant induction of Noxa or Bid by various cytotoxic or stress regimens (E Eldering and NL Alves, manuscript in preparation). Recent reports on Noxa and Puma knockout mice indicate too that Puma is essential for p53-mediated apoptosis but Noxa seems to play a more restricted role. 37, 38, 48 It is noteworthy that on average, cells expressing mutated IgV H genes clearly displayed a more profound upregulation of Puma upon drug treatment compared to cells expressing unmutated IgV H genes. This separation was not reflected in apoptosis read out under the experimental conditions used. This is consistent with our view on the delicate balance between proand antiapoptotic regulators in CLL, because the mere synthesis of additional apoptogenic proteins such as Puma will suffice to shift the balance towards apoptosis in an in vitro setting. In samples with proven dysfunctional p53, the drug-induced Puma upregulation was absent. Thus, although the IgV H mutated and unmutated patient groups displayed distinct magnitudes of Puma induction, this cannot be simply explained by p53 mutation or dysfunction. Previous studies reported an association between p53 status and response to therapy. 20, 23 Indeed, a preliminary report also associates IgV H status with response to chemotherapy, 49 consistent with our in vitro data which suggest that this could be linked to the degree of Puma upregulation. Alternatively, the distinction in p53/Puma-responses may merely reflect independent differences intrinsic to the developmental stage in which the cells became malignant. Thus, although the functional significance of a link between BCRsignaling and p53-activation is presently unclear, our observations provide a basis for further studies into the relation between BCR signaling, p53-mediated Puma upregulation and IgV H mutation status in CLL.
